Atomo is Leading the Future of Diagnostics

Our unique, patented proprietary technologies improve rapid diagnostics testing by elevating ease-of-use and performance.

Atomo’s innovative Rapid Diagnostic Test (RDT) platforms simplify procedures, mitigate common user errors and enhance test performance. Atomo products are currently approved for distribution in more than 130 countries around the world.

Finished rapid test products are commercialized under Atomo's own brand or under private labels via partners and regional distributors. We hold regulatory approvals including CE Mark in the EU / UK, Australian TGA, and the World Health Organization with near-term opportunities for FDA approval.

Our Products in the Global Market

COVID-19 Test

Atomo’s platform is a natural fit for a fast, accurate point of care diagnostic for COVID-19. Atomo offers an antigen test for the qualitative detection of nucleocapsid protein antigens specific to the SARS-CoV-2 virus, as well as an antibody test to indicate if a user has protection from the virus.

COVID-19 Rapid Antigen Test

Sold in Australia & New Zealand
A fast, accurate point of care COVID-19 antigen test for the qualitative detection of nucleocapsid protein antigens specific to the SARS-CoV-2 virus.

COVID-19 Rapid Antibody Test

Sold in Australia
Branded & Distributed by NG Biotech for sale in Europe
A fast, accurate point of care COVID-19 antibody test to indicate exposure to the virus on Atomo’s integrated easy to use platform.

HIV 1&2 Test

Atomo offers the world’s first integrated, blood-based rapid diagnostic test (RDT) for HIV screening. Recognized globally for innovative design, performance and ease-of-use. With 99.6% specificity, 99.6% sensitivity, low blood volume and a 24 month shelf life, this test could save 40,000 lives per year in Africa alone.

AtomoRapid HIV 1&2 Self-Test

The only HIV self test approved by the Australian Therapeutic Goods Administration (TGA).

Simplitude ByMe HIV 1&2 Self-Test

Designed & Manufactured by Atomo; Branded & Distributed by Owen Mumford
Sold in Europe

HIV 1&2 Self-Test for Global Health

Designed & Manufactured by Atomo; Branded & Distributed by Viatris Inc.
Sold in lower and middle income markets

Iyeza HIV 1&2 Self-Test

Designed, Manufactured by Atomo; Branded and distributed by Iyeza Health
Sold in private sector markets in South Africa, Swaziland, Lesotho and Mozambique

Pregnancy Test

NG Biotech, an ambitious company intent on being a global leader in its field, partnered with Atomo to bring its pregnancy rapid diagnostic test to market.

NG-Test Blood Precision hCG Pregnancy Test

Test platform designed & manufactured by Atomo; Branded & Distributed by NG Biotech
Sold in Europe
The test offers results in 5 minutes through professional use channels. The blood-based format is more secure and reliable than urine, and saves over 85 minutes in potential Emergency Room time.

Respiratory Test

Lumos Diagnostic, partnered with Atomo to develop a novel, rapid, point-of-care test that differentiates between viral versus bacterial acute respiratory infection in 10 minutes.

FebriDx Antimicrobial Resistance (AMR) Screening Test

FebriDx Antimicrobial Resistance (AMR) Screening Test
Test platform designed & manufactured by Atomo; Branded & Distributed by Lumos
Sold in Europe and under review with the US FDA
authorized to identify and differentiate viral from bacterial acute respiratory infection. With 99% accuracy, this test has reduced antibiotic prescriptions by 80%, leading to better efficiencies and lower costs.

Finished rapid test products are commercialized under Atomo's own brand or under private labels via partners and regional distributors. We hold regulatory approvals including CE Mark in the EU/ UK, Australian TGA, and the World Health Organization with FDA approvals pending.

Develop Future Tests With Us

Atomo’s unique technology presents an opportunity to improve existing products on the market with superior usability. Our integrated platforms can help users easily perform the tests on their own and improve performance, speed and reliability in a professional clinical setting.

We welcome dialogue with forward-thinking diagnostic partners who would like to explore co-developing tests for infectious diseases, allergy sensitivities, women’s health, men’s health, sexual health, heart health and other applications.

Re-imaging diagnostics.